Key Patient Considerations for the Utilization of Intravenous and Subcutaneous Therapies

Jill Zouzoulas, MD, FACR, opens a discussion highlighting use of biologics in her practice.

A medical expert shares critical insights around biologic utilization.

Dr. Zouzoulas discusses key patient considerations to consider when deciding on an intravenous or subcutaneous biologic.

An expert rheumatologist highlights the billing process for patients receiving biologic therapies, as well as a study that highlights patient reported outcomes in patients with inflammatory arthritis utilizing intravenous biologics.

Jill Zouzoulas, M.D., FACR, describes the best practices for incorporating patient perspectives when determining the ideal route of administration for those with rheumatologic diseases.

An expert in the field of rheumatology predicts how the treatment landscape will evolve for intravenous and subcutaneous therapies.

Dr. Jennifer Seminerio discusses what what her overall perspective with intravenous biologics in gastrointestinal diseases

An expert gastroenterologist highlights what her experience has been like with subcutaneous biologics.

Dr. Seminerio uncovers what excited her about IV biologics when they first came to market.

A leading gastroenterologist highlights her initial thoughts about subcutaneous biologics.

Dr. Seminerio talks about how she positions intravenous and subcutaneous biologics and which patients benefit from each route of administration.

A gastroenterologist speaks about patient adherence when utilizing intravenous biologics.

Dr Seminerio highlights the differences in billing between intravenous and subcutaneous biologics.

An expert clinician expands on efficacy results seen in a study comparing intravenous and subcutaneous biologics.

Key topics in cost of intravenous and subcutaneous biologics are discussed by Dr Seminerio.

An expert gastroenterologist dissects a study that analyzed patient experience with intravenous and subcutaneous biological therapies.

A gastroenterologist discusses the role of biosimilars in her clinical practice.

Dr. Seminerio predicts how the future landscape will change for intravenous and subcutaneous biologics.

Jill Zouzoulas, M.D., of Tryon Medical Partners in Charlotte, North Carolina, and Jennifer Seminerio, M.D., of University of Southern Florida Health in Tampa, Florida, discussed the biologics and the pros and cons of the intravenous and subcutaneous delivery methods in Managed Healthcare Executive’s K-Cast video series.